2026
LIB-101 憑藉其獨特的多重造血修復能力，已獲得美國政府 BARDA 資助，用於開發急性輻射症候群（ARS）之醫療對策。
本次合作將結合福島當地的核災醫療經驗，評估 LIB-101 對於輻射性損傷的治療潛力，這項進展不僅是麗寶新藥邁向國際臨床的重要里程碑，也進一步驗證了其在新藥開發領域的創新實力。
In compliance with EU personal data protection laws, we are committed to protecting and providing you with control over your personal data. By clicking "Accept All", you allow us to place cookies to enhance your experience on this site, help us analyze site performance and usage, and enable us to deliver relevant marketing content. You can manage your cookie settings below. By clicking "Agree" you agree to the current settings. For more information, please visit the Privacy Statement.
This website uses cookies
In compliance with EU personal data protection laws, we are committed to protecting your personal data and providing you with control over it. By clicking "Agree", you allow us to place cookies to improve your experience on this site, help us analyze site performance and usage, and allow us to deliver relevant marketing content.
By clicking "Only necessary" you allow us to place only necessary cookies. The website cannot function without these cookies and you cannot switch them off on your system. These cookies are typically set only in response to an action you perform (i.e. a service request), such as setting privacy preferences, logging in, or filling in a form. You can set your browser to block or prompt you for these cookies, but this may prevent some site features from working.
